A clinical-stage (Phase IIb cleared by the FDA) cell therapy company targeting neurodegenerative diseases (Progressive MS, ALS). To date, over 120 patients, and 6 published clinical trials have demonstrated unprecedented improvements in disability & key biomarkers.